Most previous reports to analyze risk factors for peritoneal recurrence in patients with colon cancer have been observational studies of a population-based cohort.
This study aimed to determine the risk factors for peritoneal recurrence in patients with stage II to III colon cancer who underwent curative resection.
This was a pooled analysis using a combined database obtained from 3 large phase III randomized trials (N = 3714).
Individual patient data were collected from the Japanese Foundation for Multidisciplinary Treatment of Cancer clinical trials 7, 15, and 33, which evaluated the benefits of postoperative 5-fluorouracil–based adjuvant therapies in patients with locally advanced colorectal cancer.
We included patients who had stage II to III colon cancer and underwent curative resection with over D2 lymph node dissection.
Main outcomes measured were risk factors for peritoneal recurrence without other organ metastasis after curative surgery.
Peritoneal recurrence occurred in 2.3% (86/3714) of all patients undergoing curative resection. Mean duration from operation to peritoneal recurrence was 17.0 ± 10.3 months. Of these patients with peritoneal recurrence, 29 patients (34%) had recurrence in ≥1 other organ. Multivariate analysis showed that age (≥60 y: HR = 0.531; p = 0.0182), pathological T4 (HR = 3.802; p < 0.0001), lymph node involvement (HR = 3.491; p = 0.0002), and lymphadenectomy (D2: HR = 1.801; p = 0.0356) were independent predictors of peritoneal recurrence. The overall survival was lower in patients who developed peritoneal recurrence than in those with other recurrence (HR = 1.594; p = 0.002).
The regimens of adjuvant chemotherapy were limited to oral 5-fluorouracil.
Our findings clarified the risk factors for peritoneal recurrence in patients who underwent curative resection for colon cancer. See Video Abstract at http://links.lww.com/DCR/A609.
1 Department of Surgery, Keio University School of Medicine, Tokyo, Japan
2 Department of Biostatistics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
3 Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima, Japan
4 Department of Surgery, Yokohama City University, Yokohama, Japan
5 Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
6 Cancer Treatment Center, Kochi Medical School Hospital, Kochi, Japan
7 Faculty of Engineering, Tokyo University of Science, Tokyo, Japan
8 Department of Surgery, Tokai University, Isehara, Japan
9 Tokai Central Hospital, Kakamigahara, Japan
10 Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan
11 Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan
Funding/Support: This study was supported by Japanese Foundation for Multidisciplinary Treatment of Cancer and, in part, by the Epidemiological and Clinical Research Information Network.
Financial Disclosure: None reported.
Correspondence: Shuhei Mayanagi, M.D., Ph.D., Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160–8582, Japan. E-mail: firstname.lastname@example.org, or Takaki Yoshikawa, M.D., Ph.D., Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama 241–8515, Japan. E-mail: email@example.com
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.